Exercise to treat depression yields similar results to therapy and antidepressants

An updated Cochrane review of 73 randomized trials involving nearly 5,000 adults finds exercise yields a moderate reduction in depressive symptoms versus no treatment and a similar effect to psychological therapy (based on 10 trials, moderate-certainty); comparisons with antidepressant medication suggested similar effects but were low-certainty. Light-to-moderate intensity programs (13–36 sessions), mixed exercise and resistance training showed relatively greater benefit, side effects were rare, and long-term effects remain unclear due to limited follow-up; the update adds 35 trials but calls for larger, higher-quality studies.

Analysis

Market structure: The Cochrane update raises the profile of exercise as a low-cost substitute for psychotherapy and, to a lesser extent, antidepressants, which favors low-price, scalable fitness providers (budget gyms, connected fitness hardware/software, wearables) and B2B vendors that can sell “exercise as medicine” into insurers/employers. Large pharma makers of antidepressants (e.g., broad-based PFE/LLY-sized exposure) are unlikely to see material near-term revenue loss given low-certainty evidence and entrenched prescribing, but niche mental-health drug developers that rely on incremental outpatient uptake are more vulnerable over 2–5 years.

Risk assessment: Tail risks include rapid policy adoption (national prescribing guidance or insurer reimbursement for exercise programmes) within 6–24 months that reallocates outpatient therapy spend, and data showing long-term non-superiority which could reverse demand—both low probability but high impact. Hidden dependencies: adoption requires durable patient adherence and provider workflows (EHR integrations, referral networks); failure there means limited commercial upside. Near-term (0–3 months) market moves should be muted; meaningful shifts likely 6–24 months as pilots scale.

Trade implications: Direct plays are long budget/chain gyms (Planet Fitness PLNT) and wearables/health-platform leaders (AAPL) where unit economics scale; short/underweight pure-play teletherapy platforms (Teladoc TDOC) and niche antidepressant developers without diversified pipelines. Use pairs: long PLNT (consumer demand) vs short TDOC (substitution risk) over 6–12 months. Options: favor defined-risk bullish call spreads on PLNT/AAPL and defined-risk put spreads on TDOC to limit capital.

Contrarian angles: Consensus underestimates frictions—exercise efficacy depends on adherence; many patients will combine modalities, preserving pharma/therapy revenue. Reaction is underdone for B2B enablers (EHR vendors, digital therapeutics that incorporate exercise) which could see outsized wins; consider hunting small-cap vendors providing clinician-prescribed exercise platforms. Historic parallel: smoking-cessation substitutes improved outcomes but didn’t eliminate nicotine-replacement markets; expect similar coexistence here.

Key Decisions for Investors

• Establish a 2.5% portfolio long position in Planet Fitness (PLNT) over 6–12 months, targeting +30% upside if membership growth >5% YoY and same-store sales beat industry comps; trim to breakeven if SSS decline >5% in any quarter.
• Allocate 1.5% to bullish, defined-risk AAPL exposure via a 9-month call spread (buy Jul 2026 ITM/near-ATM call, sell higher strike) to play wearables/health-platform monetization — hold 6–12 months and reassess on WWDC/earnings signals on health services revenue (>10% growth target).
• Initiate a 2% pair trade: long PLNT, short Teladoc (TDOC) equal notional size — horizon 6–12 months. Exit the short if TDOC reports >10% sequential margin expansion or new payer contracts; exit the pair if PLNT misses membership growth by >3ppt.
• Buy a 6-month put spread on TDOC (defined risk) sized at 1% of portfolio to hedge the pair trade and exploit volatility; monitor regulatory/payer announcements over next 30–90 days as catalysts to widen the spread.